Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 10/2013

01-12-2013

A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada

Auteurs: Murray D. Krahn, Karen E. Bremner, Shabbir M. H. Alibhai, Andy Ni, George Tomlinson, Audrey Laporte, Gary Naglie

Gepubliceerd in: Quality of Life Research | Uitgave 10/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To measure quality of life (QOL) and utilities for prostate cancer (PC) patients and determine their predictors.

Methods

A population-based, community-dwelling, geographically diverse sample of long-term PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physician. Consenting patients completed questionnaires by mail: Health Utilities Index (HUI 2/3), Patient Oriented Prostate Utility Scale PORPUS-U (utility), PORPUS-P (health profile), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and Prostate Cancer Index (PCI). Clinical data were obtained from chart reviews. Regression models determined the effects of a series of variables on QOL and utility.

Results

We received questionnaires and reviewed charts for 585 patients (mean age 72.6, 2–13 years postdiagnosis). Mean utility scores were as follows: PORPUS-U = 0.92, HUI2 = 0.85, and HUI3 = 0.78. Mean health profile scores were as follows: PORPUS-P = 71.7, PCI sexual, urinary, and bowel function = 23.7, 79.1, and 84.6, respectively (0 = worst, 100 = best), and FACT-P = 125.1 (0 = worst, 156 = best). In multiple regression analyses, comorbidity and PCI urinary, sexual, and bowel function were significant predictors of other QOL measures. With all variables, 32–50 % of the variance in utilities was explained.

Conclusions

Many variables affect global QOL of PC survivors; only prostate symptoms and comorbidity have independent effects. Our model allows estimation of the effects of multiple factors on utilities. These utilities for long-term outcomes of PC and its treatment are valuable for decision/cost-effectiveness models of PC treatment.
vorige artikel Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing’s syndrome (ERCUSYN)
volgende artikel A comparison of directly elicited and pre-scored preference-based measures of quality of life: the case of adhesive capsulitis
Literatuur
1.
Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012). Global cancer transitions according to the human development index (2008–2030): A population-based study. The Lancet Oncology, 13, 790–801.PubMedCrossRef
2.
Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., et al. (2012). Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380, 1840–1850.PubMedCrossRef
3.
Allard, C. B., Dason, S., Lusis, J., & Kapoor, A. (2012). Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Canadian Urological Association Journal, 6(3), 188–193.PubMedCrossRef
4.
Barry, M. J. (2009). Screening for prostate cancer—the controversy that refuses to die. New England Journal of Medicine, 360, 1351–1354.PubMedCrossRef
5.
Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011). Active surveillance for prostate cancer: Progress and promise. Journal of Clinical Oncology, 29, 3669–3676.PubMedCrossRef
6.
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blizina, I., Fu, R., et al. (2011). Screening for prostate cancer: A review of the evidence for the U.S. preventive services task force. Annals of Internal Medicine, 155, 762–771.PubMedCrossRef
7.
Lin, K., Croswell, J. M., Koenig, H., Lam, C., & Maltz, A. (2011) Prostate-specific antigen-based screening for prostate cancer: An evidence update for the U.S. preventive services task force. AHRQ publication no. 12-05160-EF-1, Oct 2011. Evidence synthesis number 90 (Screening for prostate cancer, topic page. U.S. Preventive Services Task Force. http://​www.​uspreventiveserv​icestaskforce.​org/​uspstf/​uspsprca.​htm).
8.
Albertsen, P. C. (2010). The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis. Urology, 75, 399–405.PubMedCrossRef
9.
Litwin, M. S., Gore, J. L., Kwan, K., Brandeis, J. M., Lee, S. P., Withers, H. R., et al. (2007). Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer, 109, 2239–2247.PubMedCrossRef
10.
Talcott, J. A., Manola, J., Clark, J. A., Kaplan, I., Beard, C. J., Mitchell, S. P., et al. (2003). Time course and predictors of symptoms after primary prostate cancer therapy. Journal of Clinical Oncology, 21, 3979–3986.PubMedCrossRef
11.
Revicki, D. A., & Kaplan, R. M. (1993). Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality of Life Research, 2, 477–487.PubMedCrossRef
12.
Froberg, D. G., & Kane, R. L. (1989). Methodology for measuring health-state preferences-II: Scaling methods. Journal of Clinical Epidemiology, 42, 459–471.PubMedCrossRef
13.
Feeny, D., Furlong, W., Boyle, M., & Torrance, G. W. (1995). Multi-attribute health status classification systems: Health utilities index. PharmacoEconomics, 7, 490–502.PubMedCrossRef
14.
Euroqol Group. (1990). A new facility for the measurement of health related quality of life. Health Policy, 16, 199–208.CrossRef
15.
Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Chapter 6: Cost-utility analysis. In Methods for the economic evaluation of health care programmes. New York: Oxford University Press.
16.
Heijnsdijk, E. A. M., Wever, E. M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., et al. (2012). Quality-of-life effects of prostate-specific antigen screening. New England Journal of Medicine, 367, 595–605.PubMedCrossRef
17.
Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., et al. (2010). Active surveillance compared with initial treatment for men with low-risk prostate cancer. A decision analysis. The Journal of the American Medical Association, 304, 2373–2380.CrossRef
18.
Sox, H. (2012). Quality of life and guidelines for PSA screening (editorial). New England Journal of Medicine, 367(7), 669–671.PubMedCrossRef
19.
Krahn, M., Bremner, K. E., Tomlinson, G., Ritvo, P., Irvine, J., & Naglie, G. (2007). Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Quality of Life Research, 16, 509–522.PubMedCrossRef
20.
Krahn, M. D., Ritvo, P., Irvine, J., Tomlinson, G., Bremner, K. E., Bezjak, A., et al. (2003). Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Medical Care, 41, 153–164.PubMedCrossRef
21.
Krahn, M. D., Bremner, K. E., Tomlinson, G., & Naglie, G. (2009). Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases, 12, 361–368.CrossRef
22.
Saigal, C. S., Cornbein, J., Nease, R., & Litwin, M. S. (2001). Predictors of utilities for health states in early stage prostate cancer. Journal of Urology, 166, 942–946.PubMedCrossRef
23.
Stewart, S. T., Lenert, L., Bhatnagar, V., & Kaplan, R. (2005). Utilities for prostate cancer health states in men aged 60 and older. Medical Care, 43(4), 347–355.PubMedCrossRef
24.
Sommers, B. D., Beard, C. J., D’Amico, A. V., Kaplan, I., Richie, J. P., & Zeckhauser, R. J. (2008). Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer, 113, 2058–2067.PubMedCrossRef
25.
Meghani, S. H., Lee, C. S., Hanlon, A. L., & Bruner, D. W. (2009). Latent class analysis to understand heterogeneity in prostate cancer treatment utilities. BMC Medical Informatics and Decision Making, 9, 47.PubMedCrossRef
26.
McTaggart-Cowan, H. (2011). Elicitation of informed general population health state utility values: A review of the literature. Value in Health, 14, 1153–1157.PubMedCrossRef
27.
Shimizu, F., Fujino, K., Ito, Y. M., Fukuda, T., Kawachi, Y., Minowada, S., et al. (2008). Factors associated with variation in utility scores among patients with prostate cancer. Value in Health, 11, 1190–1193.PubMedCrossRef
28.
Smith, D. S., Krygiel, J., Nease, R. F., Jr, Sumner, W. II, & Catalona, W. J. (2002). Patient preferences for outcomes associated with surgical management of prostate cancer. Journal of Urology, 167, 2117–2122.PubMedCrossRef
29.
Jayadevappa, R., Schwartz, J. S., Chhatre, S., Wein, A. J., & Malkowicz, S. B. (2010). Association between utility and treatment among patients with prostate cancer. Quality of Life Research, 19, 711–720.PubMedCrossRef
30.
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917.CrossRef
31.
Hall, S., Schulze, K., Groome, P., McKillop, W., & Holowaty, E. (2006). Using cancer registry data for survival studies: The example of the Ontario cancer registry. Journal of Clinical Epidemiology, 59, 67–76.PubMedCrossRef
32.
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373–383.PubMedCrossRef
33.
Krahn, M., Ritvo, P., Irvine, J., Tomlinson, G., Bezjak, A., Trachtenberg, J., et al. (2000). Construction of the patient-oriented prostate utility scale (PORPUS): A multiattribute health state classification system for prostate cancer. Journal of Clinical Epidemiology, 53, 920–930.PubMedCrossRef
34.
Tomlinson, G., Bremner, K. E., Ritvo, P., Naglie, G., & Krahn, M. D. (2012). Development and validation of a utility weighting function for the Patient-Oriented Prostate Utility Scale (PORPUS). Medical Decision Making, 32, 11–30.PubMedCrossRef
35.
Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40, 113–128.PubMedCrossRef
36.
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50, 920–928.PubMedCrossRef
37.
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Medical Care, 36, 1002–1012.PubMedCrossRef
38.
Cabrol, M. P. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
39.
SAS Inc. SAS 9.1.3 for Windows. Cary, NC, USA.
40.
Van Buuren, S., & Oudshoorn, CGM. (1999) Flexible multivariate imputation by MICE. Leiden: TNO preventie en Gezondheid, TNO/VGZ/PG 99054.
41.
Crook, J., Borg, J., Evans, A., Toi, A., Saibishkumar, E. P., Fung, S., et al. (2011). 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. International Journal of Radiation Oncology Biology Physics, 80, 1323–1329.CrossRef
42.
Crook, J., Lukka, H., Klotz, L., Bestic, N., Johnston, M., & The Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. (2001). Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. Canadian Medical Association Journal, 164, 975–981.PubMed
43.
Kopec, J. A., Williams, J. I., To, T., & Austin, P. C. (2000). Measuring population health: Correlates of the health utilities index among English and French Canadians. Canadian Journal of Public Health, 91, 465–470.PubMed
44.
Maddigan, S. L., Feeny, D. H., & Johnson, J. A. (2005). Health related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Quality of Life Research, 14, 1311–1320.PubMedCrossRef
45.
Bremner, K. E., Chong, C. A. K. Y., Tomlinson, G., Alibhai, S. M. H., & Krahn, M. D. (2007). A review and meta-analysis of prostate cancer utilities. Medical Decision Making, 27, 288–298.PubMedCrossRef
46.
Statistics Canada. (2006) Census of population. Statistics Canada catalogue no. 97-560-XCB2006008 (Ontario, Code35) Date modified: 2011-04-07.
47.
Statistics Canada. (2006). Catalogue number 97-563-XCB2006005.2006 census.
48.
Sterne, J. A., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., et al. (2009). Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. British Medical Journal, 338, b2393. doi:10.​1136/​bmj.​b2393.PubMedCrossRef
49.
Willis, D. L., Gonzalgo, M. L., Brotzman, M., Feng, Z., Trock, B., & Su, L.-M. (2011). Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: A study of comparative effectiveness based upon validated quality of life outcomes. BJU International, 109, 898–905.PubMedCrossRef
50.
Wilson, T., & Torrey, R. (2011). Open versus robotic-assisted radical prostatectomy: Which is better? Current Opinion in Urology, 21, 200–205.PubMedCrossRef
51.
Al-Mamgani, A., Heemsbergen, W. D., Peeters, S. T., & Lebesque, J. V. (2009). Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 73, 685–691.CrossRef
52.
Zelefsky, M. J., Levin, E. J., Hunt, M., Yamada, Y., Shippy, A. M., Jackson, A., et al. (2008). Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 70, 1124–1129.CrossRef
Metagegevens
Titel
A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada
Auteurs
Murray D. Krahn
Karen E. Bremner
Shabbir M. H. Alibhai
Andy Ni
George Tomlinson
Audrey Laporte
Gary Naglie
Publicatiedatum
01-12-2013
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 10/2013
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0401-1

Andere artikelen Uitgave 10/2013

Quality of Life Research 10/2013 Naar de uitgave

Original Paper

Quality of life and time perspective in inflammatory bowel disease patients

OriginalPaper

Self-rated health and life satisfaction among Canadian adults: associations of perceived weight status versus BMI

OriginalPaper

Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing’s syndrome (ERCUSYN)

OriginalPaper

An assessment of validity and responsiveness of generic measures of health-related quality of life in hearing impairment

OriginalPaper

Mindfulness: a systematic review of instruments to measure an emergent patient-reported outcome (PRO)

OriginalPaper

Factor analyses of the Hospital Anxiety and Depression Scale: a Bayesian structural equation modeling approach